Referencing European prices for Medicare Part B drugs is a possible approach for drug pricing regulation in the US. If implemented, European health technology assessments will play a central role in defining prices for Medicare Part B drugs. In this session, IGES institute will provide an overview of the different types of health technology assessment frameworks in Europe. Key topics will be the differences in pricing results between various European member states and how referencing these prices would affect the pricing of Medicare Part B drugs. EUCOPE will provide an overview on the challenges of the existing European reference price system for European patients and payers and will share experiences that have been gained in Europe since the system was established.